Cambridge Innovation Capital

TRIMTECH Therapeutics is a biotechnology company focused on developing targeted protein degradation therapies to treat neurodegenerative diseases. Their innovative platform aims to degrade toxic protein aggregates, offering oral therapeutics with high specificity, a strong safety profile, and potential for personalized treatment approaches. This enables patients to access effective and safe treatments for neurological, inflammatory, and oncological conditions.

Salience Labs specializes in developing hybrid photonic-electronic chips aimed at enhancing AI data center infrastructure. The company emerged from extensive research at the University of Oxford and the University of Münster, focusing on silicon photonics to meet the increasing demands of AI workloads. Salience Labs' flagship product is an optical switch that enables all-optical networking between compute nodes, effectively addressing data movement bottlenecks. This innovation provides low-latency, high-bandwidth networking, which accelerates job completion while minimizing power consumption and costs. Additionally, the company offers high-speed multi-chip processors that integrate photonics with standard electronics, allowing for on-chip processing using photons instead of electrons. This approach significantly reduces power requirements and supports a transformation in the hardware necessary to harness the full potential of AI technologies.

Forefront RF is a fabless semiconductor company specializing in radio frequency technology. The company focuses on simplifying the design of multi-band smartphones, wearables, and Internet of Things (IoT) devices. By developing advanced radio frequency components, Forefront RF enhances the ability of these devices to receive weak signals while transmitting, thereby increasing their market reach and accessibility.

Epitopea is a transatlantic biotechnology company focused on developing immunotherapies that target a novel class of tumor‑specific antigens. Using a proprietary pipeline that combines immunopetidomics, mass spectrometry, genomics and bioinformatics, the company identifies conserved, aberrantly expressed antigens hidden in cancer’s ‘junk’ DNA. These Cryptigen TSAs are shared across patients with the same cancer indication, allowing therapies to selectively eliminate malignant cells while sparing healthy tissue, with the goal of providing durable, low‑side‑effect treatments.

Nuclera is a biotechnology company specializing in an automated protein prototyping system aimed at enhancing drug discovery processes. Its eProtein Discovery system enables researchers to rapidly produce and test high-quality, soluble, and active proteins, significantly accelerating protein projects. By integrating technology such as cell-free protein synthesis and digital microfluidics, Nuclera provides a high-throughput platform for automated protein access. This innovative approach allows scientists to obtain reliable proteins within a short timeframe, facilitating faster progress in their research and contributing to more efficient drug development efforts.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

Riverlane is a developer of quantum computing software focused on transforming experimental technology into commercial products. The company engineers innovative instruments in collaboration with quantum computer manufacturers, addressing the need for new hardware and software tools to manage the instability of qubits and rectify system defects at unprecedented speeds. Riverlane's software includes an ultra-low latency quantum operating system that accelerates quantum-classical hybrid algorithms, supporting hardware research and development. Additionally, the company creates algorithms designed to optimize the use of the entire quantum computing stack, assisting hardware partners in minimizing the system errors that currently challenge quantum computing capabilities.

Pragmatic is a developer of ultra-low-cost flexible integrated circuits, known as FlexICs, which are thinner than human hair and can be seamlessly embedded in various objects. This innovative technology allows designers to create application-specific flexible devices efficiently and at a fraction of the cost and time compared to traditional silicon circuits. Pragmatic also offers standard FlexIC products that enhance established applications like RFID and NFC, facilitating the creation of smart objects that can interact with consumers and their environments. The company's manufacturing is powered by the FlexLogIC production system, which enables cost-effective, high-volume production with significantly lower capital investments compared to conventional silicon fabrication methods. Pragmatic's technology is being increasingly adopted by a diverse range of global companies in markets such as consumer goods, retail, healthcare, pharmaceuticals, gaming, and security. Headquartered in Cambridge, UK, Pragmatic operates its first billion-unit production facility in Sedgefield.

Secondmind Ltd. is a software development company based in Cambridge, United Kingdom, founded in 2016. The company specializes in machine learning technology to assist automotive innovators in designing cleaner, more sustainable vehicles. Its core product, the Secondmind Decision Engine, is a cloud-based platform that empowers users to predict, plan, and manage complex decisions while navigating the intricacies of engineering design, particularly during the transition to electrification. By leveraging advanced machine learning algorithms, Secondmind aims to enhance the design, development, and driving experience of vehicles, ultimately contributing to the goal of carbon-neutral mobility. Formerly known as Prowler.io Limited, the company rebranded in October 2020 and has established itself as a leader in applying practical machine learning research to the automotive sector.

T-Therapeutics is a biopharmaceutical company focused on developing engineered soluble biologics for oncological and immunological applications. The company utilizes a proprietary T cell receptor (TCR) discovery platform based on a highly humanized mouse model, which allows access to TCRs for human antigens that are typically unavailable from human samples. This innovative approach enables the binding of specific peptide-MHC (pMHC) targets on cells, facilitating the recruitment of T cells to combat cancer or modulate immune responses. Through its advanced capabilities in mouse genome engineering, single-cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance the quality of life for patients suffering from chronic and infectious diseases. The company's culture emphasizes creativity and collaboration, fostering an environment conducive to groundbreaking research and development in the biopharmaceutical field.

CMR Surgical, established in 2014 and headquartered in Cambridge, UK, specializes in designing and manufacturing medical devices for minimal access surgery. The company's primary product is the Versius surgical robotic system, which facilitates laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback. CMR Surgical aims to make minimal access surgery universally accessible and affordable by expanding the range of procedures that can be performed using its robotic systems.

Riverlane is a developer of quantum computing software focused on transforming experimental technology into commercial products. The company engineers innovative instruments in collaboration with quantum computer manufacturers, addressing the need for new hardware and software tools to manage the instability of qubits and rectify system defects at unprecedented speeds. Riverlane's software includes an ultra-low latency quantum operating system that accelerates quantum-classical hybrid algorithms, supporting hardware research and development. Additionally, the company creates algorithms designed to optimize the use of the entire quantum computing stack, assisting hardware partners in minimizing the system errors that currently challenge quantum computing capabilities.

Complement Therapeutics is a preclinical stage biotechnology company focused on addressing chronic diseases linked to the dysregulation of the complement system. The company has developed a precision medicine diagnostic platform that stratifies patients according to their complement-activation profiles. This innovative approach not only facilitates patient selection for future clinical trials but also serves as an efficacy biomarker, potentially enhancing medical treatment outcomes. By leveraging its platform methodology, Complement Therapeutics aims to improve the precision of treatments for patients suffering from conditions influenced by complement system dysregulation.

Mosaic Therapeutics is reshaping the interface of computational and experimental medicine to power new medicines for patients.

Seldon is a company that specializes in machine learning deployment, providing a platform designed to enhance the efficiency of data science workflows. Its software allows machine learning engineering teams to transition from research and development to production with significant time savings. By utilizing prototyping algorithms and models, Seldon's technology can convert machine learning models into production-ready microservices, specifically REST and GRPC, facilitating faster data interpretation. The company serves a diverse range of large enterprises across various sectors, including technology, pharmaceuticals, automotive, finance, and retail. Additionally, Seldon is known for its open-source projects that focus on model serving, explanations, and monitoring, contributing to the deployment and management of machine learning models.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Carrick Therapeutics, Ltd. is a Dublin-based company founded in 2015 that specializes in the development of innovative cancer therapeutics. The company focuses on targeting molecular pathways associated with aggressive and resistant forms of cancer. By employing advanced mechanisms, Carrick Therapeutics aims to transform cancer treatment and improve patient outcomes. Their approach facilitates the early detection of predictive biomarkers, allowing for timely initiation of personalized treatments.

Cambridge GaN Devices specializes in the design, development, and commercialization of gallium nitride (GaN) power devices aimed at enhancing energy efficiency across various electronic applications. The company produces a range of GaN-based semiconductor products that significantly improve power conversion and minimize energy loss in systems used in sectors such as renewable energy, electric vehicles, and consumer electronics. These transistors are characterized by their speed, reduced power loss, smaller size compared to traditional silicon alternatives, and greater energy storage and conversion capabilities. By collaborating with industry partners, Cambridge GaN Devices promotes innovation and facilitates the adoption of its advanced technology within the power semiconductor market, contributing to the advancement of greener technologies.

Unlikely AI is an innovative company focused on advancing artificial intelligence technology through a unique and bold approach. The company develops a product-centric platform that can engage with users and provide explanations, facilitating the creation of AI products that perform tasks previously deemed impossible for computers. By pushing the boundaries of AI capabilities, Unlikely AI aims to reshape the interaction between humans and machines, contributing to the ongoing evolution of the field.

Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to address the underlying causes of mitochondrial dysfunction through a thorough understanding of mitochondrial mechanisms. By creating innovative treatments, Pretzel Therapeutics seeks to provide effective solutions for a range of diseases, particularly those related to aging. The company is dedicated to advancing the field of mitochondrial medicine and improving patient outcomes through targeted therapeutic approaches.

Salience Labs specializes in developing hybrid photonic-electronic chips aimed at enhancing AI data center infrastructure. The company emerged from extensive research at the University of Oxford and the University of Münster, focusing on silicon photonics to meet the increasing demands of AI workloads. Salience Labs' flagship product is an optical switch that enables all-optical networking between compute nodes, effectively addressing data movement bottlenecks. This innovation provides low-latency, high-bandwidth networking, which accelerates job completion while minimizing power consumption and costs. Additionally, the company offers high-speed multi-chip processors that integrate photonics with standard electronics, allowing for on-chip processing using photons instead of electrons. This approach significantly reduces power requirements and supports a transformation in the hardware necessary to harness the full potential of AI technologies.

Epitopea is a transatlantic biotechnology company focused on developing immunotherapies that target a novel class of tumor‑specific antigens. Using a proprietary pipeline that combines immunopetidomics, mass spectrometry, genomics and bioinformatics, the company identifies conserved, aberrantly expressed antigens hidden in cancer’s ‘junk’ DNA. These Cryptigen TSAs are shared across patients with the same cancer indication, allowing therapies to selectively eliminate malignant cells while sparing healthy tissue, with the goal of providing durable, low‑side‑effect treatments.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to address the underlying causes of mitochondrial dysfunction through a thorough understanding of mitochondrial mechanisms. By creating innovative treatments, Pretzel Therapeutics seeks to provide effective solutions for a range of diseases, particularly those related to aging. The company is dedicated to advancing the field of mitochondrial medicine and improving patient outcomes through targeted therapeutic approaches.

PetMedix Ltd is a veterinary biopharmaceutical company based in Hinxton, United Kingdom, that specializes in therapeutic drug discovery for pets. Founded in 2017, the company utilizes advanced scientific techniques to develop innovative antibody therapies aimed at improving the health and well-being of companion animals. PetMedix has created specialized platforms, including the Ky9 and Felyne transgenic mouse systems, which are designed to produce therapeutic-quality antibodies tailored for pets. This approach allows for the generation of a diverse repertoire of antibodies that mirrors the immune systems of companion animals, enabling veterinarians to administer safe and effective monoclonal antibody treatments. By applying over thirty years of expertise in human drug development to veterinary medicine, PetMedix is dedicated to enhancing the quality of life for pets through cutting-edge therapies.

CMR Surgical, established in 2014 and headquartered in Cambridge, UK, specializes in designing and manufacturing medical devices for minimal access surgery. The company's primary product is the Versius surgical robotic system, which facilitates laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback. CMR Surgical aims to make minimal access surgery universally accessible and affordable by expanding the range of procedures that can be performed using its robotic systems.

Origami is a technology company focused on revolutionizing the energy sector through smart technology. The company's mission is to create a green energy world by providing intelligent trading and automation software that helps energy companies navigate the complexities of renewable energy markets. Origami's real-time data platform offers a suite of solutions powered by machine learning, designed to enhance efficiency, resilience, and profitability in power production, planning, and energy trading. By optimizing physical, financial, and contractual positions, Origami enables clients to reduce risk, improve visibility, and capture valuable opportunities within the evolving energy landscape.

Sense Biodetection Limited is a molecular diagnostics company based in Abingdon, United Kingdom, established in 2013. The company specializes in developing user-centered, handheld diagnostic tests aimed at enhancing healthcare decisions and processes, particularly in the areas of infections and oncology. Its flagship product, True Point-of-Care, utilizes advanced molecular methods, including polymerase chain reaction (PCR), to deliver rapid and accurate results. This capability allows clinics and medical professionals to detect infections swiftly and make informed treatment decisions in a decentralized healthcare setting, ultimately improving patient outcomes.

Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.

Riverlane is a developer of quantum computing software focused on transforming experimental technology into commercial products. The company engineers innovative instruments in collaboration with quantum computer manufacturers, addressing the need for new hardware and software tools to manage the instability of qubits and rectify system defects at unprecedented speeds. Riverlane's software includes an ultra-low latency quantum operating system that accelerates quantum-classical hybrid algorithms, supporting hardware research and development. Additionally, the company creates algorithms designed to optimize the use of the entire quantum computing stack, assisting hardware partners in minimizing the system errors that currently challenge quantum computing capabilities.

Secondmind Ltd. is a software development company based in Cambridge, United Kingdom, founded in 2016. The company specializes in machine learning technology to assist automotive innovators in designing cleaner, more sustainable vehicles. Its core product, the Secondmind Decision Engine, is a cloud-based platform that empowers users to predict, plan, and manage complex decisions while navigating the intricacies of engineering design, particularly during the transition to electrification. By leveraging advanced machine learning algorithms, Secondmind aims to enhance the design, development, and driving experience of vehicles, ultimately contributing to the goal of carbon-neutral mobility. Formerly known as Prowler.io Limited, the company rebranded in October 2020 and has established itself as a leader in applying practical machine learning research to the automotive sector.

Seldon is a company that specializes in machine learning deployment, providing a platform designed to enhance the efficiency of data science workflows. Its software allows machine learning engineering teams to transition from research and development to production with significant time savings. By utilizing prototyping algorithms and models, Seldon's technology can convert machine learning models into production-ready microservices, specifically REST and GRPC, facilitating faster data interpretation. The company serves a diverse range of large enterprises across various sectors, including technology, pharmaceuticals, automotive, finance, and retail. Additionally, Seldon is known for its open-source projects that focus on model serving, explanations, and monitoring, contributing to the deployment and management of machine learning models.

Congenica Ltd. is a biotechnology company that specializes in clinical data solutions for genetic diagnosis. Established in 2012 and headquartered in Hinxton, United Kingdom, it offers the Sapientia platform, a clinical genomic analytics tool that integrates human DNA sequences with deep clinical phenotyping. This platform enables clinicians and researchers to interpret genetic diseases and provides actionable insights for diagnosis, prognosis, and research. Additionally, Sapientia supports personalized medicine by facilitating the creation of disease registries, identifying patient populations for clinical studies, and aiding in the discovery of novel drug targets and biomarkers. Congenica's focus is on improving clinical outcomes through advanced genomic analysis.

GeoSpock Limited, established in 2013 and headquartered in Cambridge, UK, with offices in Tokyo and Singapore, specializes in developing a unique, cloud-native database platform, GeoSpock DB. This platform is optimized for querying and analyzing large-scale, location-tagged data, enabling efficient data fusion and rapid, complex queries using SQL. It integrates seamlessly with popular business intelligence tools and data science environments, empowering users to unlock insights from diverse IoT data sources, from real-time fleet tracking to local service applications.

AudioTelligence Ltd is a company based in Cambridge, United Kingdom, specializing in advanced audio processing technology. Founded in 2017, AudioTelligence focuses on developing software that enhances the clarity and intelligibility of audio captured from multiple microphones, addressing the challenges posed by loud background noise in conversations. The company employs a data-driven technique known as blind audio signal separation, which significantly outperforms traditional methods such as beamforming and deep neural networks. This innovative technology aims to improve automatic speech recognition (ASR) systems, enabling businesses to provide clearer and more understandable speech for both users and voice-activated devices.

Sense Biodetection Limited is a molecular diagnostics company based in Abingdon, United Kingdom, established in 2013. The company specializes in developing user-centered, handheld diagnostic tests aimed at enhancing healthcare decisions and processes, particularly in the areas of infections and oncology. Its flagship product, True Point-of-Care, utilizes advanced molecular methods, including polymerase chain reaction (PCR), to deliver rapid and accurate results. This capability allows clinics and medical professionals to detect infections swiftly and make informed treatment decisions in a decentralized healthcare setting, ultimately improving patient outcomes.

CMR Surgical, established in 2014 and headquartered in Cambridge, UK, specializes in designing and manufacturing medical devices for minimal access surgery. The company's primary product is the Versius surgical robotic system, which facilitates laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback. CMR Surgical aims to make minimal access surgery universally accessible and affordable by expanding the range of procedures that can be performed using its robotic systems.

Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.

PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. Established in 2017, the company offers PredictSURE IBD, a diagnostic tool designed to identify patients with Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, who are at risk of severe, relapsing disease. This simple lab test requires only a small blood sample and provides critical insights that enable healthcare providers to tailor early biologic therapies for at-risk patients. By delivering personalized treatment options, PredictImmune aims to improve disease management and clinical outcomes for individuals suffering from IBD, addressing an important need recognized by physicians, patients, and payors alike.

Riverlane is a developer of quantum computing software focused on transforming experimental technology into commercial products. The company engineers innovative instruments in collaboration with quantum computer manufacturers, addressing the need for new hardware and software tools to manage the instability of qubits and rectify system defects at unprecedented speeds. Riverlane's software includes an ultra-low latency quantum operating system that accelerates quantum-classical hybrid algorithms, supporting hardware research and development. Additionally, the company creates algorithms designed to optimize the use of the entire quantum computing stack, assisting hardware partners in minimizing the system errors that currently challenge quantum computing capabilities.

Audio Analytic Ltd., established in 2008, specializes in developing sound recognition software for consumer electronics. Based in Cambridge, UK, with an office in San Francisco, the company offers embedded software platforms, ai3™ and ai3-nano™, which enable products like smart speakers, video doorbells, and earbuds to understand and respond to their environment through sound. Their software is licensed to leading consumer tech companies, providing context-based intelligence to enhance user experiences.

Secondmind Ltd. is a software development company based in Cambridge, United Kingdom, founded in 2016. The company specializes in machine learning technology to assist automotive innovators in designing cleaner, more sustainable vehicles. Its core product, the Secondmind Decision Engine, is a cloud-based platform that empowers users to predict, plan, and manage complex decisions while navigating the intricacies of engineering design, particularly during the transition to electrification. By leveraging advanced machine learning algorithms, Secondmind aims to enhance the design, development, and driving experience of vehicles, ultimately contributing to the goal of carbon-neutral mobility. Formerly known as Prowler.io Limited, the company rebranded in October 2020 and has established itself as a leader in applying practical machine learning research to the automotive sector.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

PolyProx Therapeutics Ltd is a biotechnology company based in Cambridge, United Kingdom, founded in 2018. It focuses on researching and developing innovative drug therapies aimed at treating cancer and neurodegenerative diseases. The company's flagship product, Polyproxin, utilizes engineered proteins that selectively target tumor cells. This mechanism activates the natural degradation processes within the cells, allowing for the removal of disease-causing proteins. By employing this novel approach, PolyProx aims to provide effective treatment options for cancer patients, potentially improving their outcomes and quality of life.

Cytora is a London-based company that offers a configurable platform designed to enhance the efficiency and accuracy of risk processing for commercial insurers. Founded in 2014, Cytora's platform digitizes incoming risks and enriches them with various data sources. It evaluates these risks using multiple criteria, including appetite and priority rules, and subsequently routes them for automated or manual underwriting. By leveraging artificial intelligence, Cytora's platform learns the patterns of different risks and loss outcomes over time, allowing it to compute ranks, scores, and prices for properties and organizations. This capability enables insurers to better target profitable risks, improve risk selection, and optimize pricing strategies.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, that specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment. Founded in 2014, Inivata has developed TAm-Seq technology, which enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples. This innovative approach, known as liquid biopsy, provides a significant advancement over traditional invasive biopsies by allowing for easier detection, monitoring, and treatment of cancer. Inivata's platform aims to assist oncologists in making informed treatment decisions by improving the understanding of cancer dynamics, including monitoring treatment responses and detecting relapses. The company has established a strategic collaboration with NeoGenomics, Inc. to further its mission in the field of cancer genomics.

Pragmatic is a developer of ultra-low-cost flexible integrated circuits, known as FlexICs, which are thinner than human hair and can be seamlessly embedded in various objects. This innovative technology allows designers to create application-specific flexible devices efficiently and at a fraction of the cost and time compared to traditional silicon circuits. Pragmatic also offers standard FlexIC products that enhance established applications like RFID and NFC, facilitating the creation of smart objects that can interact with consumers and their environments. The company's manufacturing is powered by the FlexLogIC production system, which enables cost-effective, high-volume production with significantly lower capital investments compared to conventional silicon fabrication methods. Pragmatic's technology is being increasingly adopted by a diverse range of global companies in markets such as consumer goods, retail, healthcare, pharmaceuticals, gaming, and security. Headquartered in Cambridge, UK, Pragmatic operates its first billion-unit production facility in Sedgefield.

Imagen Ltd, established in 1991 and based in Willingham, UK, specializes in designing and developing media archive management solutions. The company offers three primary products: Imagen2, a comprehensive media asset management and publishing system; ImagenCloud, a cloud-based solution for managing and publishing videos and images; and Orbital, a compliance recording system. Its client portfolio includes prominent organizations such as the Ministry of Defence, The Police, BBC, ITN, Imperial War Museum, British Telecom, and British Pathé. Imagen Ltd operates under its current name since August 2015, following a rebrand from Cambridge Imaging Systems Limited.

Morphogen-IX Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative treatments for pulmonary arterial hypertension (PAH), a severe and life-limiting condition that affects lung blood vessels and can lead to heart failure. Founded in 2015, Morphogen-IX is pioneering the use of bone morphogenetic proteins, particularly BMP9 and BMP10, to enhance BMPR-II receptor signaling in endothelial cells, which is crucial for addressing the underlying mechanisms of PAH. Current therapies primarily alleviate symptoms rather than addressing the disease's root causes, leaving patients with limited options. The company employs a semi-virtual model, leveraging a network of experienced professionals in drug discovery to maximize capital efficiency while maintaining high-quality research and development.

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, specializing in the development of a novel class of medicines known as Bicycles. These are synthetic short peptides designed to form two loops that stabilize their structure. The company's lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) currently undergoing Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also a BTC in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies targeting Nectin-4. Additionally, Bicycle is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to address therapeutic areas such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. Bicycle Therapeutics was incorporated in 2009 and aims to address significant unmet medical needs in oncology and beyond.

CEDAR Audio is a leading company specializing in audio restoration and speech enhancement for various applications, including film, television, radio broadcasting, and audio forensic investigation. Established in 1988 in Cambridge, UK, following extensive research funded by the British Library National Sound Archive, the company maintains strong ties to Cambridge University, benefiting from the expertise of its Directors, including two university professors. CEDAR Audio is dedicated to advancing the science and technology of audio restoration, producing many of the industry's top products while actively engaging in research to develop innovative techniques. The company focuses on delivering high-quality customer support and has received numerous accolades for its service excellence. Its hardware-based restoration systems are designed to suppress noise in diverse live settings, such as conferences, performances, and sporting events, enabling sound recordists to achieve clean, noise-free audio production.

AudioTelligence Ltd is a company based in Cambridge, United Kingdom, specializing in advanced audio processing technology. Founded in 2017, AudioTelligence focuses on developing software that enhances the clarity and intelligibility of audio captured from multiple microphones, addressing the challenges posed by loud background noise in conversations. The company employs a data-driven technique known as blind audio signal separation, which significantly outperforms traditional methods such as beamforming and deep neural networks. This innovative technology aims to improve automatic speech recognition (ASR) systems, enabling businesses to provide clearer and more understandable speech for both users and voice-activated devices.

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, specializing in the development of a novel class of medicines known as Bicycles. These are synthetic short peptides designed to form two loops that stabilize their structure. The company's lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) currently undergoing Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also a BTC in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies targeting Nectin-4. Additionally, Bicycle is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to address therapeutic areas such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. Bicycle Therapeutics was incorporated in 2009 and aims to address significant unmet medical needs in oncology and beyond.

Nstream is a technology company that specializes in advanced analytics software designed to process data at the edge of networks. Founded in 2015 and headquartered in San Jose, California, Nstream offers products like Swim EDX and Swim Continuum, which enable organizations to gain real-time insights and predictions from streaming data. The company focuses on providing solutions for various sectors, including original equipment manufacturers, service providers, enterprises, and Internet of Things (IoT) vendors. Nstream's platform combines edge computing, machine learning, and self-training digital twins, allowing businesses to enhance decision-making and operational efficiency. By leveraging a unique stateful architecture, its products eliminate traditional database latency, ensuring rapid access to contextual data and facilitating effective operational decision support.

Undo Ltd. is a software company specializing in debugging tools aimed at enhancing developer productivity and software quality. Founded in 2005 and headquartered in Cambridge, United Kingdom, with an additional office in San Francisco, California, Undo is renowned for its innovative time travel debugging technology. This technology allows developers to review and replay the execution of software, providing them with the ability to identify and fix programming errors efficiently. Key products include LiveRecorder, which integrates seamlessly into continuous integration workflows for C/C++, Go, and Java, and UndoDB, an interactive reversible debugger designed for use with Linux and Android. Undo's solutions are employed by various sectors, including data management, networking, and electronic design automation, with notable clients comprising leading technology firms that leverage these tools to improve their development processes and software reliability.

CMR Surgical, established in 2014 and headquartered in Cambridge, UK, specializes in designing and manufacturing medical devices for minimal access surgery. The company's primary product is the Versius surgical robotic system, which facilitates laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback. CMR Surgical aims to make minimal access surgery universally accessible and affordable by expanding the range of procedures that can be performed using its robotic systems.

Origami is a technology company focused on revolutionizing the energy sector through smart technology. The company's mission is to create a green energy world by providing intelligent trading and automation software that helps energy companies navigate the complexities of renewable energy markets. Origami's real-time data platform offers a suite of solutions powered by machine learning, designed to enhance efficiency, resilience, and profitability in power production, planning, and energy trading. By optimizing physical, financial, and contractual positions, Origami enables clients to reduce risk, improve visibility, and capture valuable opportunities within the evolving energy landscape.

GeoSpock Limited, established in 2013 and headquartered in Cambridge, UK, with offices in Tokyo and Singapore, specializes in developing a unique, cloud-native database platform, GeoSpock DB. This platform is optimized for querying and analyzing large-scale, location-tagged data, enabling efficient data fusion and rapid, complex queries using SQL. It integrates seamlessly with popular business intelligence tools and data science environments, empowering users to unlock insights from diverse IoT data sources, from real-time fleet tracking to local service applications.

Cytora is a London-based company that offers a configurable platform designed to enhance the efficiency and accuracy of risk processing for commercial insurers. Founded in 2014, Cytora's platform digitizes incoming risks and enriches them with various data sources. It evaluates these risks using multiple criteria, including appetite and priority rules, and subsequently routes them for automated or manual underwriting. By leveraging artificial intelligence, Cytora's platform learns the patterns of different risks and loss outcomes over time, allowing it to compute ranks, scores, and prices for properties and organizations. This capability enables insurers to better target profitable risks, improve risk selection, and optimize pricing strategies.

CMR Surgical, established in 2014 and headquartered in Cambridge, UK, specializes in designing and manufacturing medical devices for minimal access surgery. The company's primary product is the Versius surgical robotic system, which facilitates laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback. CMR Surgical aims to make minimal access surgery universally accessible and affordable by expanding the range of procedures that can be performed using its robotic systems.

Secondmind Ltd. is a software development company based in Cambridge, United Kingdom, founded in 2016. The company specializes in machine learning technology to assist automotive innovators in designing cleaner, more sustainable vehicles. Its core product, the Secondmind Decision Engine, is a cloud-based platform that empowers users to predict, plan, and manage complex decisions while navigating the intricacies of engineering design, particularly during the transition to electrification. By leveraging advanced machine learning algorithms, Secondmind aims to enhance the design, development, and driving experience of vehicles, ultimately contributing to the goal of carbon-neutral mobility. Formerly known as Prowler.io Limited, the company rebranded in October 2020 and has established itself as a leader in applying practical machine learning research to the automotive sector.

Z Factor Limited is a drug discovery company established in 2015 with a focus on developing therapeutic agents for alpha-1-antitrypsin deficiency. Founded through a collaboration between Index Ventures and the University of Cambridge, the company is dedicated to designing innovative treatments that address the misfolding of the Z variant of alpha-1-antitrypsin. This condition presents significant medical challenges, and current treatment options are largely restricted to lung or liver transplantation and augmentation therapy. By targeting the underlying causes of the disease, Z Factor aims to fulfill a critical unmet medical need in the field of respiratory and liver health.

Congenica Ltd. is a biotechnology company that specializes in clinical data solutions for genetic diagnosis. Established in 2012 and headquartered in Hinxton, United Kingdom, it offers the Sapientia platform, a clinical genomic analytics tool that integrates human DNA sequences with deep clinical phenotyping. This platform enables clinicians and researchers to interpret genetic diseases and provides actionable insights for diagnosis, prognosis, and research. Additionally, Sapientia supports personalized medicine by facilitating the creation of disease registries, identifying patient populations for clinical studies, and aiding in the discovery of novel drug targets and biomarkers. Congenica's focus is on improving clinical outcomes through advanced genomic analysis.

Audio Analytic Ltd., established in 2008, specializes in developing sound recognition software for consumer electronics. Based in Cambridge, UK, with an office in San Francisco, the company offers embedded software platforms, ai3™ and ai3-nano™, which enable products like smart speakers, video doorbells, and earbuds to understand and respond to their environment through sound. Their software is licensed to leading consumer tech companies, providing context-based intelligence to enhance user experiences.

Exvastat is a preclinical-stage pharmaceutical company founded in 2016, focused on developing treatments for acute respiratory distress syndrome (ARDS). The company is working on a repurposed drug that is already marketed for other indications, aiming to address the critical need for effective therapies in ARDS. This innovative treatment has the potential to significantly lower mortality rates and debilitating complications associated with the syndrome, while also reducing healthcare costs for providers managing critically ill patients. By targeting the underlying causes of pulmonary edema, Exvastat seeks to improve patient outcomes and enhance the standard of care in respiratory distress scenarios.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

Imagen Ltd, established in 1991 and based in Willingham, UK, specializes in designing and developing media archive management solutions. The company offers three primary products: Imagen2, a comprehensive media asset management and publishing system; ImagenCloud, a cloud-based solution for managing and publishing videos and images; and Orbital, a compliance recording system. Its client portfolio includes prominent organizations such as the Ministry of Defence, The Police, BBC, ITN, Imperial War Museum, British Telecom, and British Pathé. Imagen Ltd operates under its current name since August 2015, following a rebrand from Cambridge Imaging Systems Limited.

Undo Ltd. is a software company specializing in debugging tools aimed at enhancing developer productivity and software quality. Founded in 2005 and headquartered in Cambridge, United Kingdom, with an additional office in San Francisco, California, Undo is renowned for its innovative time travel debugging technology. This technology allows developers to review and replay the execution of software, providing them with the ability to identify and fix programming errors efficiently. Key products include LiveRecorder, which integrates seamlessly into continuous integration workflows for C/C++, Go, and Java, and UndoDB, an interactive reversible debugger designed for use with Linux and Android. Undo's solutions are employed by various sectors, including data management, networking, and electronic design automation, with notable clients comprising leading technology firms that leverage these tools to improve their development processes and software reliability.

Pragmatic is a developer of ultra-low-cost flexible integrated circuits, known as FlexICs, which are thinner than human hair and can be seamlessly embedded in various objects. This innovative technology allows designers to create application-specific flexible devices efficiently and at a fraction of the cost and time compared to traditional silicon circuits. Pragmatic also offers standard FlexIC products that enhance established applications like RFID and NFC, facilitating the creation of smart objects that can interact with consumers and their environments. The company's manufacturing is powered by the FlexLogIC production system, which enables cost-effective, high-volume production with significantly lower capital investments compared to conventional silicon fabrication methods. Pragmatic's technology is being increasingly adopted by a diverse range of global companies in markets such as consumer goods, retail, healthcare, pharmaceuticals, gaming, and security. Headquartered in Cambridge, UK, Pragmatic operates its first billion-unit production facility in Sedgefield.

Carrick Therapeutics, Ltd. is a Dublin-based company founded in 2015 that specializes in the development of innovative cancer therapeutics. The company focuses on targeting molecular pathways associated with aggressive and resistant forms of cancer. By employing advanced mechanisms, Carrick Therapeutics aims to transform cancer treatment and improve patient outcomes. Their approach facilitates the early detection of predictive biomarkers, allowing for timely initiation of personalized treatments.

PervasID Limited is a company based in Cambridge, United Kingdom, that specializes in the development of wide area passive RFID systems. Founded in 2011, PervasID focuses on providing location capabilities based on the EPC Class1 Gen2 standard. The company emerged from research conducted in the Engineering Department at the University of Cambridge and has since successfully deployed its technology in various field trials. PervasID's innovative RFID tracking system is designed to serve multiple industries, including retail, healthcare, supply chain and logistics, and aviation. Utilizing patented technology, the system employs fixed ultra-high frequency RFID to detect passive tags over long ranges with high accuracy, enabling organizations to enhance visibility into goods, assets, and personnel, thereby streamlining operational processes.

Fluidic Analytics Limited, founded in 2013 as a spin-out from the University of Cambridge, specializes in the design, development, and manufacturing of advanced analytical tools for protein characterization. The company focuses on creating innovative products that facilitate in-solution sizing and quantification of proteins, with offerings such as Fluidity One and Fluidity One-W, which enable high sensitivity analysis of protein size and interaction kinetics. These tools are essential for a variety of applications, including assessing protein quality, interactions, and aggregation. Fluidic Analytics serves a diverse clientele, including scientists, clinics, and healthcare providers, aiming to enhance the understanding of protein behavior and its implications in biological processes. By combining cutting-edge technology with a commitment to accessibility and user data ownership, the company aspires to transform the field of protein science, paralleling the revolutionary impact of advancements in DNA sequencing.

CMR Surgical, established in 2014 and headquartered in Cambridge, UK, specializes in designing and manufacturing medical devices for minimal access surgery. The company's primary product is the Versius surgical robotic system, which facilitates laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback. CMR Surgical aims to make minimal access surgery universally accessible and affordable by expanding the range of procedures that can be performed using its robotic systems.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Origami is a technology company focused on revolutionizing the energy sector through smart technology. The company's mission is to create a green energy world by providing intelligent trading and automation software that helps energy companies navigate the complexities of renewable energy markets. Origami's real-time data platform offers a suite of solutions powered by machine learning, designed to enhance efficiency, resilience, and profitability in power production, planning, and energy trading. By optimizing physical, financial, and contractual positions, Origami enables clients to reduce risk, improve visibility, and capture valuable opportunities within the evolving energy landscape.

Audio Analytic Ltd., established in 2008, specializes in developing sound recognition software for consumer electronics. Based in Cambridge, UK, with an office in San Francisco, the company offers embedded software platforms, ai3™ and ai3-nano™, which enable products like smart speakers, video doorbells, and earbuds to understand and respond to their environment through sound. Their software is licensed to leading consumer tech companies, providing context-based intelligence to enhance user experiences.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, that specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment. Founded in 2014, Inivata has developed TAm-Seq technology, which enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples. This innovative approach, known as liquid biopsy, provides a significant advancement over traditional invasive biopsies by allowing for easier detection, monitoring, and treatment of cancer. Inivata's platform aims to assist oncologists in making informed treatment decisions by improving the understanding of cancer dynamics, including monitoring treatment responses and detecting relapses. The company has established a strategic collaboration with NeoGenomics, Inc. to further its mission in the field of cancer genomics.

Morphogen-IX Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative treatments for pulmonary arterial hypertension (PAH), a severe and life-limiting condition that affects lung blood vessels and can lead to heart failure. Founded in 2015, Morphogen-IX is pioneering the use of bone morphogenetic proteins, particularly BMP9 and BMP10, to enhance BMPR-II receptor signaling in endothelial cells, which is crucial for addressing the underlying mechanisms of PAH. Current therapies primarily alleviate symptoms rather than addressing the disease's root causes, leaving patients with limited options. The company employs a semi-virtual model, leveraging a network of experienced professionals in drug discovery to maximize capital efficiency while maintaining high-quality research and development.

Jukedeck is an artificial intelligence–driven music composition company that develops tools to create original music for videos and apps. It trains deep neural networks to understand music composition and to automatically generate and tailor scores for different scenes, moods, and timing. The platform includes an API that gives developers access to a library of royalty-free music and backing tracks, enabling users to browse, edit, and integrate music into their apps and videos. By interpreting video inputs, Jukedeck aims to provide personalized music solutions for individuals and businesses, supporting creative workflows without licensing hurdles.

GeoSpock Limited, established in 2013 and headquartered in Cambridge, UK, with offices in Tokyo and Singapore, specializes in developing a unique, cloud-native database platform, GeoSpock DB. This platform is optimized for querying and analyzing large-scale, location-tagged data, enabling efficient data fusion and rapid, complex queries using SQL. It integrates seamlessly with popular business intelligence tools and data science environments, empowering users to unlock insights from diverse IoT data sources, from real-time fleet tracking to local service applications.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Imagen Ltd, established in 1991 and based in Willingham, UK, specializes in designing and developing media archive management solutions. The company offers three primary products: Imagen2, a comprehensive media asset management and publishing system; ImagenCloud, a cloud-based solution for managing and publishing videos and images; and Orbital, a compliance recording system. Its client portfolio includes prominent organizations such as the Ministry of Defence, The Police, BBC, ITN, Imperial War Museum, British Telecom, and British Pathé. Imagen Ltd operates under its current name since August 2015, following a rebrand from Cambridge Imaging Systems Limited.

Abcodia is a biotechnology company specializing in the discovery and validation of molecular biomarkers for disease diagnosis and screening, with a particular focus on cancer. Founded in 2010 and headquartered in Cambridge, UK, Abcodia utilizes its unique longitudinal serum biobank and collaborations with academic institutions like UCL, technology platform providers, and leading diagnostic companies to support the entire diagnostic development process. The company offers Roca Test solutions for early ovarian cancer detection, serving customers across multiple states in the US and the United Kingdom.

Undo Ltd. is a software company specializing in debugging tools aimed at enhancing developer productivity and software quality. Founded in 2005 and headquartered in Cambridge, United Kingdom, with an additional office in San Francisco, California, Undo is renowned for its innovative time travel debugging technology. This technology allows developers to review and replay the execution of software, providing them with the ability to identify and fix programming errors efficiently. Key products include LiveRecorder, which integrates seamlessly into continuous integration workflows for C/C++, Go, and Java, and UndoDB, an interactive reversible debugger designed for use with Linux and Android. Undo's solutions are employed by various sectors, including data management, networking, and electronic design automation, with notable clients comprising leading technology firms that leverage these tools to improve their development processes and software reliability.

Congenica Ltd. is a biotechnology company that specializes in clinical data solutions for genetic diagnosis. Established in 2012 and headquartered in Hinxton, United Kingdom, it offers the Sapientia platform, a clinical genomic analytics tool that integrates human DNA sequences with deep clinical phenotyping. This platform enables clinicians and researchers to interpret genetic diseases and provides actionable insights for diagnosis, prognosis, and research. Additionally, Sapientia supports personalized medicine by facilitating the creation of disease registries, identifying patient populations for clinical studies, and aiding in the discovery of novel drug targets and biomarkers. Congenica's focus is on improving clinical outcomes through advanced genomic analysis.

Pragmatic is a developer of ultra-low-cost flexible integrated circuits, known as FlexICs, which are thinner than human hair and can be seamlessly embedded in various objects. This innovative technology allows designers to create application-specific flexible devices efficiently and at a fraction of the cost and time compared to traditional silicon circuits. Pragmatic also offers standard FlexIC products that enhance established applications like RFID and NFC, facilitating the creation of smart objects that can interact with consumers and their environments. The company's manufacturing is powered by the FlexLogIC production system, which enables cost-effective, high-volume production with significantly lower capital investments compared to conventional silicon fabrication methods. Pragmatic's technology is being increasingly adopted by a diverse range of global companies in markets such as consumer goods, retail, healthcare, pharmaceuticals, gaming, and security. Headquartered in Cambridge, UK, Pragmatic operates its first billion-unit production facility in Sedgefield.

Congenica Ltd. is a biotechnology company that specializes in clinical data solutions for genetic diagnosis. Established in 2012 and headquartered in Hinxton, United Kingdom, it offers the Sapientia platform, a clinical genomic analytics tool that integrates human DNA sequences with deep clinical phenotyping. This platform enables clinicians and researchers to interpret genetic diseases and provides actionable insights for diagnosis, prognosis, and research. Additionally, Sapientia supports personalized medicine by facilitating the creation of disease registries, identifying patient populations for clinical studies, and aiding in the discovery of novel drug targets and biomarkers. Congenica's focus is on improving clinical outcomes through advanced genomic analysis.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, that specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment. Founded in 2014, Inivata has developed TAm-Seq technology, which enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples. This innovative approach, known as liquid biopsy, provides a significant advancement over traditional invasive biopsies by allowing for easier detection, monitoring, and treatment of cancer. Inivata's platform aims to assist oncologists in making informed treatment decisions by improving the understanding of cancer dynamics, including monitoring treatment responses and detecting relapses. The company has established a strategic collaboration with NeoGenomics, Inc. to further its mission in the field of cancer genomics.

Origami is a technology company focused on revolutionizing the energy sector through smart technology. The company's mission is to create a green energy world by providing intelligent trading and automation software that helps energy companies navigate the complexities of renewable energy markets. Origami's real-time data platform offers a suite of solutions powered by machine learning, designed to enhance efficiency, resilience, and profitability in power production, planning, and energy trading. By optimizing physical, financial, and contractual positions, Origami enables clients to reduce risk, improve visibility, and capture valuable opportunities within the evolving energy landscape.

Jukedeck is an artificial intelligence–driven music composition company that develops tools to create original music for videos and apps. It trains deep neural networks to understand music composition and to automatically generate and tailor scores for different scenes, moods, and timing. The platform includes an API that gives developers access to a library of royalty-free music and backing tracks, enabling users to browse, edit, and integrate music into their apps and videos. By interpreting video inputs, Jukedeck aims to provide personalized music solutions for individuals and businesses, supporting creative workflows without licensing hurdles.

Imagen Ltd, established in 1991 and based in Willingham, UK, specializes in designing and developing media archive management solutions. The company offers three primary products: Imagen2, a comprehensive media asset management and publishing system; ImagenCloud, a cloud-based solution for managing and publishing videos and images; and Orbital, a compliance recording system. Its client portfolio includes prominent organizations such as the Ministry of Defence, The Police, BBC, ITN, Imperial War Museum, British Telecom, and British Pathé. Imagen Ltd operates under its current name since August 2015, following a rebrand from Cambridge Imaging Systems Limited.